It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN)* –a School of King’s College London – is Europe’s largest centre for research and postgraduate education in psychiatry, psychology, basic and clinical neuroscience.
We are world-renowned for the quality of our research and, for psychiatry and psychology, we are the most cited research centre outside the US and the second most cited research centre in the world – as ranked by Thomson ISI Essential Science Indicators. In the 2008 Research Assessment Exercise we were judged to have the highest research power of any UK institution within the areas of psychiatry, neuroscience and clinical psychology.
Our world-class research-led learning experience attracts the very best students from around the world who enjoy unrivalled learning opportunities – supported by strong partnerships with NHS trusts, industry and healthcare organisations.
This project has been carried out with the support of: 1. The GAP (Genetic and Psychosis) and PUMP study teams, Institute of Psychiatry, Psychology & Neuroscience, King’s College London; 2. The South London and Maudsley (SLaM) NHS Foundation Trust; 3. Funding was provided by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, SLaM and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London; The Psychiatry Research Trust, the Maudsley Charity Research Fund and by the European Community's Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EUGEI).
Paper reference: Di Forti, M. et al. ‘Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study’ published in Lancet Psychiatry DOI: dx.doi.org...(14)00117-5.
originally posted by: BornAgainAlien
a reply to: theabsolutetruth
No surprise here...
I have seen many who are sensitive to psychosis become that because of strong cannabis, so I can confirm that.
I`m actual really surprised they only just came to that conclusion, because I can`t even count it on two hands about how many I have been seen ending up in a mental hospital purely because of strong cannabis.
Being from The Netherlands we were able to buy it legally for several decades already.
The association between cannabis use and increased risk of developing schizophrenia-like psychosis has been consistently reported by prospective epidemiological studies.2,3 Our previous study was the first to show that use of high-potency (skunk-like) cannabis carries the highest risk for psychotic disorders. In the present larger sample analysis, we replicated
our previous report and showed that the highest probability to suffer a psychotic disorder isin those who are daily users of high potency cannabis. Indeed, skunk use appears to contribute to 24% of cases of first episode psychosis in south London
A possible limitation of our study is the absence of data on number of joints or grams used per day. However, because we collected information about use over a period of years and not about present use, the reliability of such detailed information would probably have been confounded by recall bias to a greater extent than was the general description of pattern of use that we obtained. The fact that we were able to collect detailed information on other environmental factors and control for their potential confounding effects is a key strength of our study
originally posted by: Krazysh0t
originally posted by: theabsolutetruth
a reply to: Aleister
Not one of those comments used any rational basis for their propaganda claims.
Bullcrap. Here is a great refutation of your study, complete with links to other studies and all.
What researchers have learned from these studies is that cannabis can potentially cause psychosis, but only in a select group of people who are naturally vulnerable.
Reputation and impact
The Lancet has an Impact Factor of 39·207. The journal is currently ranked second out of 150 journals in the general medicine category (2013 Journal Citation Reports®, Thomson Reuters 2014).
For papers, which will usually be primary research, judged to warrant fast dissemination, The Lancet will publish a peer-reviewed manuscript within 4 weeks of receipt.
A theoretical explanation of why skunk might have been
preferred by patients with first-episode psychosis is that,
when they began to experience their illness prodrome, these
individuals might have sought increased concentrations of
THC to self-medicate. However, experimental studies show
that THC induces psychotic symptoms, while cannabidiol
ameliorates them and reduces anxiety.16–19 That people who
already have prodromal symptoms would choose a type of
cannabis that is high in THC and has little cannabidiol
(such as skunk), which might exacerbate their symptoms,
rather than a cannabidiol-containing type (such as hash),
would seem counterintuitive.